Medicine
Zevalin kit
Zevalin kit is a prescription medicine containing Ibritumomab tiuxetan, marketed by Acrotech Biopharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store the kit at 2-8°C (36-46°F). Do not freeze.
Key facts
- Active ingredient (INN)
- Ibritumomab tiuxetan
- Brand
- Zevalin
- Dosage form
- Kit
- Packs
- 1 kit
- Marketing authorisation holder
- Acrotech Biopharma
- Manufacturer
- Acrotech Biopharma
- Origin register
- US FDA, United States
- Storage
- Store the kit at 2-8°C (36-46°F). Do not freeze.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 19 February 2002
- Identifiers
- DailyMed set ID 25d367dc-da65-44c9-a844-1bf15339c285NDC 72893-007Application BLA125019
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 carton * 10 mL in 1 vial * 2 mL in 1 vial * 2 mL in 1 vial | 72893-007-04 | Acrotech Biopharma | 19 February 2002 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 19 February 2002 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Ibritumomab tiuxetan is a prescription medicine indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), among other approved uses. It is available as kits. MedsAcross supplies Ibritumomab tiuxetan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Ibritumomab tiuxetanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Zevalin prescribing information (Acrotech Biopharma) · U.S. National Library of Medicine, DailyMed
Need Zevalin kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.